Emmecell Doses First Patient in EO2002 Trial

The phase 2 EMERALD study tests a cell therapy designed to treat corneal edema without donor tissue grafts.

Updated on Nov. 18, 2026 in Biotech

Close view of a laboratory cell-culture workbench with a glass dish of pale-amber fluid, a clear vial, and a thin metallic magnetic plate under soft daylight.
Emmecell dosed the first patient in its phase 2 EMERALD trial of EO2002, a cell therapy designed to treat corneal edema without donor tissue grafts. AI Illustration. Upload story photo >

Emmecell has dosed the first patient in its phase 2 EMERALD trial evaluating EO2002, an allogeneic human corneal endothelial cell therapy for corneal edema. The FDA granted EO2002 Regenerative Medicine Advanced Therapy designation in July 2026.

Why it matters

Corneal endothelial dysfunction causes fluid buildup, corneal swelling and impaired vision, and advanced cases often require endothelial keratoplasty, which depends on scarce donor tissue. An injectable cell therapy that restores endothelial function without a graft could widen treatment options for patients in the United States.

The EMERALD study randomizes participants to 150,000 cells, 500,000 cells or placebo, with a primary endpoint of at least a 15-letter best-corrected visual acuity gain at 26 weeks. Participants are followed for 52 weeks, and no efficacy or safety results have yet been reported.

The players

Emmecell

Emmecell is a company developing cell-based therapies for corneal disease, including EO2002, which is being evaluated as a donor-free alternative to endothelial keratoplasty.

U.S. Food and Drug Administration

The FDA is the federal agency that regulates drugs and biologics in the United States and granted EO2002 Regenerative Medicine Advanced Therapy designation.

The details

EO2002 is delivered through a single intracameral injection using Emmecell's Magnetic Cell Delivery platform, which pairs magnetically labeled corneal endothelial cells with an external magnetic patch designed to guide cells toward the endothelium and improve retention. The study is registered as NCT07729137, and Emmecell intends it to be the first of two trials in its planned registrational program.

Timeline

  1. July 2026: FDA granted EO2002 Regenerative Medicine Advanced Therapy designation.

  2. November 18, 2026: Emmecell announced the first patient dosed in the EMERALD trial.

  3. 26 weeks: Primary endpoint assessment timepoint.

  4. 52 weeks: Total participant follow-up period.

Roadmap

EO2002's RMAT designation places it within the expedited FDA pathway created under the 21st Century Cures Act for regenerative therapies. The program signals that cell-based treatments for corneal disease are moving toward registrational trials in the United States.

If the EMERALD trial succeeds, patients with corneal edema could eventually receive an injection instead of a donor corneal graft. The trial is still in an early phase, so the therapy is not yet available for treatment.

The takeaway

A donor-free cell injection for corneal swelling would be a notable shift if it reaches approval. Patients and clinicians should watch for phase 2 results before expecting any change in care.

Further reading

For more on regulatory pathways shaping new therapies, explore Biotech coverage.

Source note: This article includes information reported by Eyewire+.